Kevin Duffy
Overview
Explore the profile of Kevin Duffy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skop I, Miller C, Duffy K
Issues Law Med
. 2024 May;
39(1):32-49.
PMID: 38771713
The U.S. FDA has permanently removed the in-person prescribing requirements that previously safeguarded the use of mifepristone/misoprostol medical abortions, allowing prescribing through telemedicine or on-line ordering and distribution through the...
2.
Roddie C, Lekakis L, Marzolini M, Ramakrishnan A, Zhang Y, Hu Y, et al.
Blood
. 2023 Feb;
141(20):2470-2482.
PMID: 36821767
Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1...
3.
Raphela T, Duffy K
Zool Stud
. 2022 Dec;
61:e33.
PMID: 36568821
Invasive plant species have negative ecological impacts such as displacing indigenous plants and invertebrates. These invasive plant species affect biodiversity by impacting indigenous vegetation and the food webs associated with...
4.
Cordoba S, Onuoha S, Thomas S, Pignataro D, Hough R, Ghorashian S, et al.
Nat Med
. 2021 Oct;
27(10):1797-1805.
PMID: 34642489
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation...
5.
Frankle W, Narendran R, Wood A, Suto F, Himes M, Kobayashi M, et al.
Synapse
. 2017 Mar;
71(7).
PMID: 28245513
ONO-2952, a novel antagonist of translocator protein 18 kDa (TSPO), binds with high affinity to TSPO in rat brain and human tumor cell line membrane preparations. This study used the...
6.
Walter H, Rule S, Dyer M, Karlin L, Jones C, Cazin B, et al.
Blood
. 2015 Nov;
127(4):411-9.
PMID: 26542378
We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. There were 9...
7.
Suto F, Wood A, Kobayashi M, Komaba J, Duffy K, Bruce M
Clin Ther
. 2015 Aug;
37(9):2071-84.
PMID: 26249232
Purpose: To investigate safety, tolerability, and pharmacokinetic properties of single and multiple doses of novel translocator protein 18 kDa antagonist ONO-2952 in healthy subjects. Methods: Double-blind, placebo-controlled single (SAD) and...
8.
Galukande M, Duffy K, Bitega J, Wooding N
PLoS One
. 2014 Aug;
9(8):e104893.
PMID: 25118716
Background: Safe Male Circumcision (SMC) is a proven approach for partial protection of men from acquisition of HIV infection. Several sub-Saharan African countries have a target to circumcise 80% of...
9.
Galukande M, Duffy K, Bitega J, Rackara S, Bbaale D, Nakaggwa F, et al.
PLoS One
. 2014 Feb;
9(1):e86631.
PMID: 24489754
Background: Safe Male Circumcision is a proven approach for partial HIV prevention. Several sub Saharan African countries have plans to reach a prevalence of 80% of their adult males circumcised...
10.
Duffy K, Galukande M, Wooding N, Dea M, Coutinho A
PLoS One
. 2013 May;
8(5):e63134.
PMID: 23717402
Introduction: Modelling, supported by the USAID Health Policy Initiative and UNAIDS, performed in 2011, indicated that Uganda would need to perform 4.2 million medical male circumcisions (MMCs) to reach 80%...